American Heart Journal
Volume 159, Issue 2 , Pages 222-230.e2 , February 2010

Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)

  • Phillip D. Levy, MD, MPH

      Affiliations

    • Department of Emergency Medicine and the Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI
    • Corresponding Author InformationReprint requests: Phillip D. Levy, MD, MPH, Department of Emergency Medicine, Wayne State University School of Medicine, 4201 St Antoine, Detroit, MI 48201.
    • ,
  • Deepa Nandyal, MD

      Affiliations

    • Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI
    • ,
  • Robert D. Welch, MD, MS

      Affiliations

    • Department of Emergency Medicine and the Cardiovascular Research Institute, Wayne State University School of Medicine, Detroit, MI
    • ,
  • Jie Lena Sun, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Karen Pieper, MS

      Affiliations

    • Duke Clinical Research Institute, Durham, NC
    • ,
  • Jalal K. Ghali, MD

      Affiliations

    • Department of Cardiology, Detroit Medical Center, Detroit, MI
    • ,
  • Gregg C. Fonarow, MD, FACC

      Affiliations

    • Department of Medicine, Ahmanson-UCLA Cardiomyopathy Center, UCLA Medical Center, Los Angeles, CA
    • ,
  • Mihai Gheorgiade, MD

      Affiliations

    • Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL
    • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Department of Medicine, Duke University School of Medicine, Durham, NC

Received 29 September 2009 ,Accepted 11 November 2009.

  • Image Result

    A and B, Marginal distribution of discharge medications for (A) ischemic and (B) nonischemic.

    A and B, Marginal distribution of discharge medications for (A) ischemic and (B) nonischemic.

  • Image Result

    A to C, Kaplan-Meier curves depicting survival by subgroup for (A) the overall study population, (B) the ischemic cohort, and (C) the nonischemic cohort.

    A to C, Kaplan-Meier curves depicting survival by subgroup for (A) the overall study population, (B) the ischemic cohort, and (C) the nonischemic cohort.

  • Image Result

    A to C, Kaplan-Meier curves depicting survival by subgroup for (A) the overall study population, (B) the ischemic cohort, and (C) the nonischemic cohort.

    A to C, Kaplan-Meier curves depicting survival by subgroup for (A) the overall study population, (B) the ischemic cohort, and (C) the nonischemic cohort.

 The OPTIMIZE-HF registry is registered: www.clinicaltrials.gov, study no. NCT00344513.

 Presented at the American Heart Association Scientific Sessions, New Orleans, LA, November 2009.

PII: S0002-8703(09)00881-3

doi: 10.1016/j.ahj.2009.11.009

American Heart Journal
Volume 159, Issue 2 , Pages 222-230.e2 , February 2010

Article Tools

* Image Usage & Resolution